Toll  -like receptor  7/8 agonist, R848, exhibits antitumoral effects in a XXXX model.

@entity518 @entity0 @entity2240 @entity22532 @entity5
UNASSIGNED: Toll  -like receptors have been utilized in cancer therapeutic strategies in recent years. To the best of our knowledge, the systemic use of the @entity22532 ( @entity22532 ) agonist has not been investigated in a @entity0 model. In the current study, @entity5 growth following drug therapy was examined. Immunofluorescence and TUNEL staining were performed in order to examine the @entity5 vasculature and apoptosis, respectively. In addition, immunohistochemistry was used to assess @entity518 in @entity5 tissues. Activated CD4+  T cells in the peripheral blood were examined by flow cytometry. In the present study, it was identified that the @entity22532 agonist, R848, exhibited a robust antitumoral effect. R848 @entity5 and induced @entity5 cell apoptosis. In addition, R848 increased high mobility group box  1 expression in @entity5 tissues and activated CD4+ T cells in the peripheral blood. A synergistic antitumoral effect of R848 and the anti  -angiogenic agent, @entity2240 , was observed. The present findings suggest that the @entity22532 agonist may be a potential adjuvant to potentiate the effect of anti  -angiogenic therapy.
